OxyDial
Philadelphia, US · Founded 2022 · Delaware corporation
OxyDial develops technology to improve treatment and understanding of blood diseases, particularly sickle cell disease, for researchers and healthcare providers globally.
Founders & leadership
OS
Oleksandr ShestakovNamed on SEC filing
AA
Alexey AprelevNamed on SEC filing
Board
DA
David AlbertBoard director
JY
John YapaolaBoard director
Reported raises · per SEC filings
Form D private placements$700K disclosed across 1 round · 2026
▶$700KraisedMay 2026 · 8 investors · Other Health CareRule 506(b)
▶$700KraisedMay 2026 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Oleksandr ShestakovExecutive Officer, Director, Promoter
- Alexey AprelevExecutive Officer, Director
- David AlbertDirector
- John YapaolaDirector
- Offering amount
- $1.5M
- Amount sold
- $700K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does OxyDial do?
- OxyDial develops technology to improve treatment and understanding of blood diseases, particularly sickle cell disease, for researchers and healthcare providers globally.
- How much funding has OxyDial raised?
- OxyDial has disclosed $700K raised across 1 round.
- Where is OxyDial headquartered?
- OxyDial is headquartered in Philadelphia, US.